Literature DB >> 27586843

Selective Modulator of Cannabinoid Receptor Type 2 Reduces Memory Impairment and Infarct Size During Cerebral Hypoperfusion and Vascular Dementia.

Shalini Jayant, Bhupesh Sharma1.   

Abstract

Vascular dementia is the highly devastating neurodegenerative disorder after Alzheimer's disease (AD) and mainly found in aged people but the effectual therapeutic target is still not there. Chronic cerebral hypoperfusion (CCH) has been broadly found in vascular dementia (VaD) patients. CCH is thought to link with neurodegenerative disorders and their subsequent cognitive deteriorate on. This study has been framed to examine the role of a selective agonist of cannabinoid receptor type 2(CB2); 1-phenylisatin in CCH induced VaD. Permanent bilateral common carotid arteries ligation or two vessels occlusion (2VO) technique was used to induce CCH in rats. 2VO animals have shown significant impairment in learning-memory (Morris water maze) and in executive functioning (Attentional set-shifting test). These animals have shown a considerable reduction in brain oxidative stress (thiobarbituric reactive acid substance-TBARS; glutathione-GSH; catalase-CAT and superoxide dismutase-SOD), mitochondrial dysfunction (complexes I, II, IV) with a significant enhancement in cholinergic activity- AChE and brain infarct size2,3,5-triphenylterazolium chloride staining (TTC staining). Animals treated with 2VO have also demonstrated a considerable augmentation in brain edema (water content). Oral administration of 1-phenylisatin has significantly recuperated 2VO induced impairment in learning-memory, an increase in TBARS, GSH, CAT, SOD, mitochondrial activity with a significant reduction in AChE activity and brain damage. Administration of 1- phenylisatin has also reported recovering brain edema in these animals. These results indicate that 2VO induced CCH in rats, which was attenuated with the treatment of 1-phenylisatin. Hence, it may be suggested that modulation of cannabinoid receptor may provide benefits in CCH as cognitive impairment and VaD. Therefore, selective agonists of CB2 receptors may be a potential research target for the alleviation of VaD.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27586843     DOI: 10.2174/1567202613666160902102007

Source DB:  PubMed          Journal:  Curr Neurovasc Res        ISSN: 1567-2026            Impact factor:   1.990


  5 in total

1.  Dl-3n-butylphthalide improves spatial learning and memory in rats with vascular dementia by reducing autophagy via regulation of the mTOR signaling pathway.

Authors:  Ayong Tian; Xiaochuan Ma; Hui Li; Rongwei Zhang
Journal:  Exp Ther Med       Date:  2019-12-31       Impact factor: 2.447

Review 2.  The endocannabinoid system: 'NO' longer anonymous in the control of nitrergic signalling?

Authors:  Christopher Lipina; Harinder S Hundal
Journal:  J Mol Cell Biol       Date:  2017-04-01       Impact factor: 6.216

3.  Paeoniflorin exerts neuroprotective effects by modulating the M1/M2 subset polarization of microglia/macrophages in the hippocampal CA1 region of vascular dementia rats via cannabinoid receptor 2.

Authors:  Xian-Qin Luo; Ao Li; Xue Yang; Xiao Xiao; Rong Hu; Tian-Wen Wang; Xiao-Yun Dou; Da-Jian Yang; Zhi Dong
Journal:  Chin Med       Date:  2018-03-20       Impact factor: 5.455

Review 4.  The role of inflammasomes in vascular cognitive impairment.

Authors:  Luting Poh; Wei Liang Sim; Dong-Gyu Jo; Quynh Nhu Dinh; Grant R Drummond; Christopher G Sobey; Christopher Li-Hsian Chen; Mitchell K P Lai; David Y Fann; Thiruma V Arumugam
Journal:  Mol Neurodegener       Date:  2022-01-09       Impact factor: 14.195

Review 5.  G-Protein-Coupled Receptors and Ischemic Stroke: a Focus on Molecular Function and Therapeutic Potential.

Authors:  Zeinab Vahidinia; Mohammad Taghi Joghataei; Cordian Beyer; Mohammad Karimian; Abolfazl Azami Tameh
Journal:  Mol Neurobiol       Date:  2021-06-12       Impact factor: 5.590

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.